Report
Valens Research

A - Embedded Expectations Analysis - 2021 11 10

Agilent Technologies, Inc. (A) currently trades above historical and corporate averages relative to Uniform earnings, with a 38.8x Uniform P/E (Fwd. V/E').

At these levels, markets are pricing in expectations for Uniform ROA to reach new peaks of 30%, accompanied by 3% Uniform asset growth.

Meanwhile, analysts expect Uniform ROA to remain stable at 16%-17% levels through 2022, accompanied by 6% Uniform asset growth.

If sustained going forward, these levels would imply a stock price closer to $89, representing approximately 40% equity downside for the firm.

Moreover, the firm's most recent earnings call suggests management may have concerns about performance sustainability, China, and replacement cycles.
Underlying
Agilent Technologies Inc.

Agilent Technologies is engaged in life sciences, diagnostics and applied chemical markets. The company's segments are: Life Sciences and Applied Markets Business, which provides instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products; Diagnostics and Genomics Business, which includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses; and Agilent CrossLab Business, which spans the entire lab with its consumables and services portfolio to improve customer outcomes.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch